Benzinga's Top #PreMarket Gainers

shares gained 35.26% to $31.15 in the pre-market trading session following the announcement of a deal with

.

shares rose 9.60% to $6.05 in pre-market trading after the company said its cancer drug development collaboration with

will be extended through March 2016.

gained 9.40% to $8.15 in pre-market trading as the company reported that it has been awarded a NIH grant to develop Sickle Cell Anemia screening in developing countries.

shares surged 3.54% to $23.13 in pre-market trading after dropping 1.67% on Thursday.

shares climbed 3.14% to $197.00 in pre-market trading following the announcement of a 55% increase in Q1 2015 deliveries.